Open joint webinar with Lif on November 12 2021:
How can SciLifeLab, MAX IV and ESS contribute to drug discovery and development?
, InfraLife organized, together with partner organisation Lif, organized a joint webinar on how SciLifeLab, MAX IV and ESS can contribute to drug discovery and development.
During this webinar, the three large-scale research infrastructures – SciLifeLab, MAX IV and ESS – presented their offer to the Life Science industry in form of advanced technologies in the shape of research infrastructure, as well as relevant data support and structures. Together, they can provide technologies ranging from genomics, proteomics, genome engineering and drug discovery, to X-ray beam lines and the most powerful neutron source world-wide, to the benefit of the pharmaceutical industry.
The webinar was a joint venture between Lif and InfraLife. Lif is the trade association for the research-based pharmaceutical industry in Sweden with about 90 members and associate companies, as well as one of InfraLife’s partner organizations.
Find available speaker presentations below.
The InfraLife project
Elin Jonsson and Josefin Lundgren Gawell, project coordinators InfraLife
SciLifeLab – possibilities in drug discovery & Development
Per Arvidsson, Director Drug Discovery & Development platform, SciLifeLab
Neutron research possibilities for drug development and the European Spallation Source (ESS)
Zoë Fisher, Group Leader for Deuteration and Macromolecular Crystallisation, ES
The MAX IV synchrotron and possibilities for Life Science
Magnus Larsson, Head of Industrial Relations MAX IV